mitomycin
mitomycin: 17 clinical trials tracked.
mitomycin evidence translation
What we can confirm
17 tracked trials
What it means
What to watch
Prepared research question
What is verified about mitomycin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 4 study sponsors
Related indications
Clinical Trials (17)showing 10 most recent
Investigation of Mitomycin C PIPAC - FOLFIRI Combination for Unresectable Appendiceal or Colorectal Peritoneal Metastases Treatment (IMPACT): A Multicenter, Randomized, Open-Label, Phase 3 Trial
Primary endpoint: Overall survival (OS)
GEMINI: Phase II Study Using Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors
Primary endpoint: Progression Free Survival (PFS)
Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer: A Phase III Multi-arm, Randomized and Controlled Clinical Trial (FOXHIPECT4)
Primary endpoint: Disease-free survival absolute
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
Primary endpoint: Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
A Multicenter, Phase III, Randomized Controlled Clinical Trial of Sintilimab Versus Mitomycin in Combination With Capecitabine and Intensity-Modulated Radiotherapy in the Treatment of Limited-stage Anal Squamous Cell Carcinoma
Primary endpoint: Clinical Complete Response (cCR) Rate
The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)
Primary endpoint: Bladder-intact event-free survival (BI-EFS)
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
Primary endpoint: Disease-free Survival (DFS)
A Single Blinded Randomised Controlled Study to Evaluate the Non-inferiority of HIPEC With Mitomycin C 10 mg/m2 for 60 Minutes Versus HIPEC With Mitomycin C 35mg/m2 for 90 Minutes in the Treatment of Pseudomyxoma Peritonei From Perforated Epithelial Mucinous Tumours of the Appendix
Primary endpoint: Disease Free Survival
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
Primary endpoint: Disease Free Survival (DFS)
17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)
Primary endpoint: Disease-free Survival (DFS)